174 related articles for article (PubMed ID: 19628666)
1. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.
Marney AM; Ma J; Luther JM; Ikizler TA; Brown NJ
J Am Soc Nephrol; 2009 Oct; 20(10):2246-52. PubMed ID: 19628666
[TBL] [Abstract][Full Text] [Related]
2. Vascular B1 kinin receptors in patients with congestive heart failure.
Lang NN; Cruden NL; Tse GH; Bloomfield P; Ludlam CA; Fox KA; Newby DE
J Cardiovasc Pharmacol; 2008 Nov; 52(5):438-44. PubMed ID: 19033823
[TBL] [Abstract][Full Text] [Related]
3. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men.
Chia S; Ludlam CA; Fox KA; Newby DE
J Am Coll Cardiol; 2003 Jan; 41(2):333-9. PubMed ID: 12535831
[TBL] [Abstract][Full Text] [Related]
4. Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
LeFebvre J; Shintani A; Gebretsadik T; Petro JR; Murphey LJ; Brown NJ
J Pharmacol Exp Ther; 2007 Mar; 320(3):1261-7. PubMed ID: 17182977
[TBL] [Abstract][Full Text] [Related]
5. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass.
Pretorius M; Scholl FG; McFarlane JA; Murphey LJ; Brown NJ
Clin Pharmacol Ther; 2005 Nov; 78(5):477-85. PubMed ID: 16321614
[TBL] [Abstract][Full Text] [Related]
6. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.
Balaguer JM; Yu C; Byrne JG; Ball SK; Petracek MR; Brown NJ; Pretorius M
Clin Pharmacol Ther; 2013 Apr; 93(4):326-34. PubMed ID: 23361105
[TBL] [Abstract][Full Text] [Related]
7. Endogenous bradykinin and the renin and pressor responses to furosemide in humans.
Murphey LJ; Kumar S; Brown NJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):644-8. PubMed ID: 11046100
[TBL] [Abstract][Full Text] [Related]
8. Bradykinin stimulates tissue plasminogen activator release in human vasculature.
Brown NJ; Gainer JV; Stein CM; Vaughan DE
Hypertension; 1999 Jun; 33(6):1431-5. PubMed ID: 10373228
[TBL] [Abstract][Full Text] [Related]
9. Effect of chronic bradykinin B2 receptor blockade on blood pressure of conscious Dahl salt-resistant rats.
Mukai H; Fitzgibbon WR; Ploth DW; Margolius HS
Br J Pharmacol; 1998 May; 124(1):197-205. PubMed ID: 9630360
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
[TBL] [Abstract][Full Text] [Related]
11. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
[TBL] [Abstract][Full Text] [Related]
12. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Genomics; 2007 Mar; 89(3):362-9. PubMed ID: 17207964
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Koh KK; Ahn JY; Han SH; Kim DS; Jin DK; Kim HS; Shin MS; Ahn TH; Choi IS; Shin EK
J Am Coll Cardiol; 2003 Sep; 42(5):905-10. PubMed ID: 12957441
[TBL] [Abstract][Full Text] [Related]
15. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
Salobir B; Sabovic M; Zupan IP; Ponikvar JB
Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients.
Costa E; Rocha S; Rocha-Pereira P; Castro E; Reis F; Teixeira F; Miranda V; Do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
J Vasc Access; 2008; 9(4):248-53. PubMed ID: 19085894
[TBL] [Abstract][Full Text] [Related]
17. The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells.
Pawluczyk IZ; Patel SR; Harris KP
Kidney Int; 2004 Apr; 65(4):1240-51. PubMed ID: 15086463
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
Chia S; Qadan M; Newton R; Ludlam CA; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):695-701. PubMed ID: 12692009
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Irish AB
Metabolism; 1997 Jan; 46(1):36-40. PubMed ID: 9005966
[TBL] [Abstract][Full Text] [Related]
20. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
